Switch to:

Arrowhead Pharmaceuticals EV-to-EBITDA

: -153.75 (As of Today)
View and export this data going back to 1997. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arrowhead Pharmaceuticals's enterprise value is $4,328.2 Mil. Arrowhead Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-28.2 Mil. Therefore, Arrowhead Pharmaceuticals's EV-to-EBITDA for today is -153.75.

NAS:ARWR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -167.9   Med: -3.8   Max: 624.9
Current: -153.75

-167.9
624.9

During the past 13 years, the highest EV-to-EBITDA of Arrowhead Pharmaceuticals was 624.90. The lowest was -167.90. And the median was -3.80.

NAS:ARWR's EV-to-EBITDA is ranked lower than
99.99% of the 275 Companies
in the Biotechnology industry.

( Industry Median: 29.35 vs. NAS:ARWR: -153.75 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2020-09-28), Arrowhead Pharmaceuticals's stock price is $44.92. Arrowhead Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was $-0.25. Therefore, Arrowhead Pharmaceuticals's PE Ratio for today is .

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Arrowhead Pharmaceuticals EV-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Arrowhead Pharmaceuticals Annual Data
Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -5.62 -8.05 -31.65 37.06

Arrowhead Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.83 37.06 118.72 449.72 -147.42

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Arrowhead Pharmaceuticals EV-to-EBITDA Distribution

* The bar in red indicates where Arrowhead Pharmaceuticals's EV-to-EBITDA falls into.



Arrowhead Pharmaceuticals EV-to-EBITDA Calculation

Arrowhead Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4328.221/-28.151
=-153.75

Arrowhead Pharmaceuticals's current Enterprise Value is $4,328.2 Mil.
Arrowhead Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was 10.72 (Sep. 2019 ) + -3.593 (Dec. 2019 ) + -20.869 (Mar. 2020 ) + -14.409 (Jun. 2020 ) = $-28.2 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Arrowhead Pharmaceuticals  (NAS:ARWR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Arrowhead Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=44.92/-0.25
=

Arrowhead Pharmaceuticals's share price for today is $44.92.
Arrowhead Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was 0.11 (Sep. 2019 ) + -0.03 (Dec. 2019 ) + -0.2 (Mar. 2020 ) + -0.13 (Jun. 2020 ) = $-0.25.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Arrowhead Pharmaceuticals EV-to-EBITDA Related Terms


Arrowhead Pharmaceuticals EV-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)